Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.Aaron Lisberg, Steven M. Dubinett, Gregory A. Fishbein et al.|Journal of Clinical Oncology|2021Cited by 2
Abstract CT219: Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i> gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)Bin Liu, Steven M. Dubinett, Fereidoun Abtin et al.|Cancer Research|2022Cited by 1
Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injectionsBin Liu, Steven M. Dubinett, Fereidoun Abtin et al.|Cancer Research|2024Cited by 1